Do Tung Dac
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Do Tung Dac has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Jorge Luis Espinoza
Faculty of Health Sciences, Kanazawa University, Kanazawa, Japan
9 shared publications Hoang Thao Giang Nguyen
5 shared publications- Akiyoshi Takami
Department of Hematology, Aichi Medical University, Nagakute, Aichi, Japan
2 shared publications Eriko Morishita
Faculty of Health Sciences, Kanazawa University, Kanazawa, Japan
2 shared publicationsJulia Nakano
Faculty of Health Sciences, Kanazawa University, Kanazawa, Japan
2 shared publicationsNguyen Hoang Viet
Faculty of Medical Technology, Hanoi Medical University, Hanoi, Vietnam
2 shared publications
Latest Publications
- Open Access
- 28 July 2026
- Published by MDPI AG in Applied Sciences
- Vol. 16 (15) , 7515
Green Tea (Camellia sinensis) Consumption and Human Immune Function: A Systematic Review of Immunomodulatory and Anti-Inflammatory Effects
Background: Green tea (Camellia sinensis) is widely consumed around the world, particularly in East Asia, and has traditionally been used to support cardiovascular and metabolic health. Rich in catechins—most notably epigallocatechin-3-gallate (EGCG)—green tea is recognized for its potential immunomodulatory and anti-inflammatory effects. However, evidence from human studies remains inconsistent, and the distinction between functional immune outcomes and systemic inflammatory markers has not been systematically evaluated. Methods: We conducted a systematic review in accordance with PRISMA guidelines, searching PubMed, Google Scholar, Cochrane Library, and EBSCO from inception to the most recent date. Eligible studies included human investigations evaluating green tea or catechin intake and reporting either immune response outcomes (e.g., natural killer cell activity, T cell responses) or systemic inflammatory markers (e.g., C-reactive protein, cytokines). Randomized controlled trials (RCTs), non-randomized interventional studies, and observational analyses were included. Data were synthesized narratively due to heterogeneity. Results: Nineteen studies (≈6800 participants) were included, comprising 12 RCTs, three non-randomized interventions, and five observational studies. Eight studies assessed immune responses and consistently demonstrated enhanced immune activity, including increased natural killer cell function and augmented γδ T cell responses. Eleven studies evaluated inflammatory markers and showed heterogeneous results: several trials reported reductions in C-reactive protein and related biomarkers, particularly in high-risk populations, whereas others found no significant changes in cytokines such as interleukin-6 or tumor necrosis factor-α. Observational studies generally reported inverse associations between tea consumption and inflammation. Green tea was well tolerated across studies. Conclusions: Green tea consumption appears to enhance functional immune responses while exerting modest, context-dependent anti-inflammatory effects. These findings support a dual immunomodulatory role and highlight the importance of distinguishing between immune function and systemic inflammation in nutritional research.
- 28 July 2026
- Published by MDPI AG in Applied Sciences
- Vol. 16 (15) , 7515
Open AccessGreen Tea (Camellia sinensis) Consumption and Human Immune Function: A Systematic Review of Immunomodulatory and Anti-Inflammatory Effects
Background: Green tea (Camellia sinensis) is widely consumed around the world, particularly in East Asia, and has traditionally been used to support cardiovascular and metabolic health. Rich in catechins—most notably epigallocatechin-3-gallate (EGCG)—green tea is recognized for its potential immunomodulatory and anti-inflammatory effects. However, evidence from human studies remains inconsistent, and the distinction between functional immune outcomes and systemic inflammatory markers has not been systematically evaluated. Methods: We conducted a systematic review in accordance with PRISMA guidelines, searching PubMed, Google Scholar, Cochrane Library, and EBSCO from inception to the most recent date. Eligible studies included human investigations evaluating green tea or catechin intake and reporting either immune response outcomes (e.g., natural killer cell activity, T cell responses) or systemic inflammatory markers (e.g., C-reactive protein, cytokines). Randomized controlled trials (RCTs), non-randomized interventional studies, and observational analyses were included. Data were synthesized narratively due to heterogeneity. Results: Nineteen studies (≈6800 participants) were included, comprising 12 RCTs, three non-randomized interventions, and five observational studies. Eight studies assessed immune responses and consistently demonstrated enhanced immune activity, including increased natural killer cell function and augmented γδ T cell responses. Eleven studies evaluated inflammatory markers and showed heterogeneous results: several trials reported reductions in C-reactive protein and related biomarkers, particularly in high-risk populations, whereas others found no significant changes in cytokines such as interleukin-6 or tumor necrosis factor-α. Observational studies generally reported inverse associations between tea consumption and inflammation. Green tea was well tolerated across studies. Conclusions: Green tea consumption appears to enhance functional immune responses while exerting modest, context-dependent anti-inflammatory effects. These findings support a dual immunomodulatory role and highlight the importance of distinguishing between immune function and systemic inflammation in nutritional research.
- 16 July 2026
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 176, 104936
Recurrent miscarriage and thrombosis in Asian antiphospholipid syndrome: a systematic review
- 16 July 2026
- Published by Elsevier in Journal of Reproductive Immunology
- Vol. 176, 104936
Recurrent miscarriage and thrombosis in Asian antiphospholipid syndrome: a systematic review
- 30 June 2026
- Published by Elsevier in Mental Health & Prevention
- Vol. 43
Regional Heterogeneity in Climate–Suicide Associations: A 20-Year Prefecture-Level Panel Study in Japan
- 30 June 2026
- Published by Elsevier in Mental Health & Prevention
- Vol. 43
Regional Heterogeneity in Climate–Suicide Associations: A 20-Year Prefecture-Level Panel Study in Japan
- Open Access
- 15 June 2026
- Published by MDPI AG in Marine Drugs
- Vol. 24 (6) , 213
Ascophyllan Supplementation Is Safe and Associated with Exploratory Modulation of Innate Immune Phenotypes, Biochemical Parameters, and the Gut Microbiome in a Randomized Pilot Trial
Background: Ascophyllan, a sulfated polysaccharide extracted from brown seaweed, has shown immunomodulatory and antioxidant effects in preclinical studies, yet human clinical evidence remains scarce. This randomized, double-blind, placebo-controlled pilot trial evaluated the safety and exploratory biological effects of daily ascophyllan supplementation in healthy adults. Methods: Twelve participants were randomized to receive either ascophyllan (n = 6) or placebo (n = 6) for 28 days. Safety was monitored through adverse event reporting and repeated laboratory assessments, including hematology, biochemistry, and inflammatory markers. Immune cell populations were analyzed via serial flow cytometry, serum total antioxidant capacity was measured at multiple time points, and gut microbiome composition was profiled using 16S rRNA gene sequencing. All analyses were exploratory in nature. Results: Ascophyllan supplementation proved well tolerated, with no adverse events observed and stable hematologic, renal, and biochemical parameters throughout the study. Exploratory longitudinal analyses suggested directional modulation of NK-cell-associated phenotypes during ascophyllan supplementation, including directional changes in CD57+, NKp46+, and NKG2D+ NK-cell phenotypes; however, group × time interaction analyses did not remain statistically significant after correction for multiple comparisons. Serum antioxidant capacity showed inter-individual variability with a directional but non-significant increase in the ascophyllan group at intermediate time points. Exploratory microbiome analyses suggested modest directional compositional differences involving members of the Bacteroidaceae and Bifidobacteriaceae families; however, no taxon remained statistically significant after correction for multiple comparisons. Conclusions: These preliminary findings indicate that ascophyllan is safe and well tolerated in healthy adults and may be associated with modulation of innate immune phenotypes, subtle microbiome compositional differences, and directional changes in antioxidant capacity. Larger, adequately powered clinical trials are warranted to confirm these observations and further investigate potential biological and clinical effects.
- 15 June 2026
- Published by MDPI AG in Marine Drugs
- Vol. 24 (6) , 213
Open AccessAscophyllan Supplementation Is Safe and Associated with Exploratory Modulation of Innate Immune Phenotypes, Biochemical Parameters, and the Gut Microbiome in a Randomized Pilot Trial
Background: Ascophyllan, a sulfated polysaccharide extracted from brown seaweed, has shown immunomodulatory and antioxidant effects in preclinical studies, yet human clinical evidence remains scarce. This randomized, double-blind, placebo-controlled pilot trial evaluated the safety and exploratory biological effects of daily ascophyllan supplementation in healthy adults. Methods: Twelve participants were randomized to receive either ascophyllan (n = 6) or placebo (n = 6) for 28 days. Safety was monitored through adverse event reporting and repeated laboratory assessments, including hematology, biochemistry, and inflammatory markers. Immune cell populations were analyzed via serial flow cytometry, serum total antioxidant capacity was measured at multiple time points, and gut microbiome composition was profiled using 16S rRNA gene sequencing. All analyses were exploratory in nature. Results: Ascophyllan supplementation proved well tolerated, with no adverse events observed and stable hematologic, renal, and biochemical parameters throughout the study. Exploratory longitudinal analyses suggested directional modulation of NK-cell-associated phenotypes during ascophyllan supplementation, including directional changes in CD57+, NKp46+, and NKG2D+ NK-cell phenotypes; however, group × time interaction analyses did not remain statistically significant after correction for multiple comparisons. Serum antioxidant capacity showed inter-individual variability with a directional but non-significant increase in the ascophyllan group at intermediate time points. Exploratory microbiome analyses suggested modest directional compositional differences involving members of the Bacteroidaceae and Bifidobacteriaceae families; however, no taxon remained statistically significant after correction for multiple comparisons. Conclusions: These preliminary findings indicate that ascophyllan is safe and well tolerated in healthy adults and may be associated with modulation of innate immune phenotypes, subtle microbiome compositional differences, and directional changes in antioxidant capacity. Larger, adequately powered clinical trials are warranted to confirm these observations and further investigate potential biological and clinical effects.
- Open Access
- 4 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 5076
The Prognostic Value of Circulating Tumor DNA for Clinical Outcomes in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
Relapse remains the leading cause of treatment failure following hematopoietic cell transplantation (HCT) for hematologic malignancies. Circulating tumor DNA (ctDNA) has emerged as a promising minimally invasive biomarker for measurable residual disease (MRD) assessment and early relapse detection; however, the prognostic significance of ctDNA in the post-transplant setting has not been comprehensively synthesized. We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines and registered the protocol in PROSPERO (CRD420261392100). PubMed, Embase, Web of Science, EBSCO, Cochrane CENTRAL, and supplementary sources were searched through November 2025. Eligible studies evaluated tumor-specific ctDNA or tumor-informed/tumor-associated cfDNA in patients undergoing allogeneic or autologous HCT for hematologic malignancies. Random-effects meta-analyses were performed for relapse/progression, overall survival (OS), and relapse-free/progression-free survival (RFS/PFS). Studies evaluating total cfDNA quantity, methylation-based cfDNA profiling, cfRNA, or chimerism-only monitoring were synthesized narratively. Ten observational cohort studies comprising 883 patients met inclusion criteria. Across acute leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes, ctDNA/cfDNA positivity was consistently associated with adverse outcomes. The pooled hazard ratio (HR) for relapse or disease progression was 12.57 (95% CI: 4.59–34.46; p < 0.001), while pooled HRs were 7.45 (95% CI: 4.11–13.48; p < 0.001) for OS and 4.46 (95% CI: 2.22–8.97; p < 0.001) for RFS/PFS. Although statistical heterogeneity was low, interpretation was limited by the relatively small number of studies contributing to each pooled endpoint. Narrative evidence additionally suggested that broader circulating nucleic acid approaches may provide complementary information regarding graft-versus-host disease, infection, and other post-transplant complications. Tumor-specific ctDNA positivity is consistently associated with increased relapse risk and inferior survival outcomes following HCT. These findings support further investigation of ctDNA-based MRD monitoring as a promising non-invasive biomarker for post-transplant molecular surveillance and risk stratification. However, prospective multicenter validation studies, assay standardization, and ctDNA-guided interventional trials remain necessary before routine clinical implementation can be recommended.
- 4 June 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (11) , 5076
Open AccessThe Prognostic Value of Circulating Tumor DNA for Clinical Outcomes in Patients Undergoing Hematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis
Relapse remains the leading cause of treatment failure following hematopoietic cell transplantation (HCT) for hematologic malignancies. Circulating tumor DNA (ctDNA) has emerged as a promising minimally invasive biomarker for measurable residual disease (MRD) assessment and early relapse detection; however, the prognostic significance of ctDNA in the post-transplant setting has not been comprehensively synthesized. We conducted a systematic review and meta-analysis in accordance with PRISMA guidelines and registered the protocol in PROSPERO (CRD420261392100). PubMed, Embase, Web of Science, EBSCO, Cochrane CENTRAL, and supplementary sources were searched through November 2025. Eligible studies evaluated tumor-specific ctDNA or tumor-informed/tumor-associated cfDNA in patients undergoing allogeneic or autologous HCT for hematologic malignancies. Random-effects meta-analyses were performed for relapse/progression, overall survival (OS), and relapse-free/progression-free survival (RFS/PFS). Studies evaluating total cfDNA quantity, methylation-based cfDNA profiling, cfRNA, or chimerism-only monitoring were synthesized narratively. Ten observational cohort studies comprising 883 patients met inclusion criteria. Across acute leukemias, lymphomas, multiple myeloma, and myelodysplastic syndromes, ctDNA/cfDNA positivity was consistently associated with adverse outcomes. The pooled hazard ratio (HR) for relapse or disease progression was 12.57 (95% CI: 4.59–34.46; p < 0.001), while pooled HRs were 7.45 (95% CI: 4.11–13.48; p < 0.001) for OS and 4.46 (95% CI: 2.22–8.97; p < 0.001) for RFS/PFS. Although statistical heterogeneity was low, interpretation was limited by the relatively small number of studies contributing to each pooled endpoint. Narrative evidence additionally suggested that broader circulating nucleic acid approaches may provide complementary information regarding graft-versus-host disease, infection, and other post-transplant complications. Tumor-specific ctDNA positivity is consistently associated with increased relapse risk and inferior survival outcomes following HCT. These findings support further investigation of ctDNA-based MRD monitoring as a promising non-invasive biomarker for post-transplant molecular surveillance and risk stratification. However, prospective multicenter validation studies, assay standardization, and ctDNA-guided interventional trials remain necessary before routine clinical implementation can be recommended.
- 28 January 2026
- Published by Elsevier in Microbial Risk Analysis
- Vol. 31
Climate-driven modeling of Japanese spotted fever, an emerging tick-borne disease
- 28 January 2026
- Published by Elsevier in Microbial Risk Analysis
- Vol. 31
Climate-driven modeling of Japanese spotted fever, an emerging tick-borne disease
- 6 January 2026
- Published by Springer Nature in Immunogenetics
- Vol. 78 (1) , 2
NKG2D genetic variants and cancer susceptibility: Integrating case-control evidence with meta-analysis
Lymphomas are biologically heterogeneous malignancies with multifactorial etiologies involving genetic, environmental, and immune dysregulation. The functional variant rs1049174 SNP in the KLRK1 gene (encoding NKG2D) regulates NKG2D expression and modulates NK cells immune surveillance pathways, which may influence lymphoma susceptibility. We investigated this association through a two-stage case-control study and meta-analysis. First, we analyzed 246 diffuse large B-cell lymphoma (DLBCL) patients and 599 healthy controls (exploratory cohort), followed by a confirmatory cohort of 234 non-Hodgkin lymphoma (NHL)/Hodgkin lymphoma (HL) patients. Genotype frequencies were assessed via chi-square tests, with odds ratios (ORs) calculated for risk associations. A systematic review and meta-analysis of 10 studies, including our cohorts (3,785 cases and 4,129 controls), testing rs1049174 and cancer risk was also conducted. In the exploratory cohort, the GG genotype showed no significant association with overall lymphoma risk (OR = 0.83; 95% CI: 0.61–1.13; *p* = 0.25). However, in NHL, the GG genotype was underrepresented (OR = 0.75; 95% CI: 0.57–0.99; *p* = 0.02). Pooled lymphoma analysis revealed a protective effect (OR = 0.78; 95% CI: 0.62–0.99; *p* = 0.03). Meta-analysis confirmed a significant protective role of the GG genotype against cancer (OR = 0.71; 95% CI: 0.63–0.79), despite heterogeneity and potential publication bias. Our findings suggest that the rs1049174 GG genotype is associated with reduced lymphoma susceptibility, particularly in NHL, underscoring the importance of immunogenetic variants in lymphomagenesis. Further functional and clinical studies are needed to elucidate the mechanistic basis of this association. Graphical Abstract
- 6 January 2026
- Published by Springer Nature in Immunogenetics
- Vol. 78 (1) , 2
NKG2D genetic variants and cancer susceptibility: Integrating case-control evidence with meta-analysis
Lymphomas are biologically heterogeneous malignancies with multifactorial etiologies involving genetic, environmental, and immune dysregulation. The functional variant rs1049174 SNP in the KLRK1 gene (encoding NKG2D) regulates NKG2D expression and modulates NK cells immune surveillance pathways, which may influence lymphoma susceptibility. We investigated this association through a two-stage case-control study and meta-analysis. First, we analyzed 246 diffuse large B-cell lymphoma (DLBCL) patients and 599 healthy controls (exploratory cohort), followed by a confirmatory cohort of 234 non-Hodgkin lymphoma (NHL)/Hodgkin lymphoma (HL) patients. Genotype frequencies were assessed via chi-square tests, with odds ratios (ORs) calculated for risk associations. A systematic review and meta-analysis of 10 studies, including our cohorts (3,785 cases and 4,129 controls), testing rs1049174 and cancer risk was also conducted. In the exploratory cohort, the GG genotype showed no significant association with overall lymphoma risk (OR = 0.83; 95% CI: 0.61–1.13; *p* = 0.25). However, in NHL, the GG genotype was underrepresented (OR = 0.75; 95% CI: 0.57–0.99; *p* = 0.02). Pooled lymphoma analysis revealed a protective effect (OR = 0.78; 95% CI: 0.62–0.99; *p* = 0.03). Meta-analysis confirmed a significant protective role of the GG genotype against cancer (OR = 0.71; 95% CI: 0.63–0.79), despite heterogeneity and potential publication bias. Our findings suggest that the rs1049174 GG genotype is associated with reduced lymphoma susceptibility, particularly in NHL, underscoring the importance of immunogenetic variants in lymphomagenesis. Further functional and clinical studies are needed to elucidate the mechanistic basis of this association. Graphical Abstract
- 16 October 2025
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 21 (11) , 1643-1655
Interleukin-17 and transplant immunology: clinical evidence from hematopoietic cell transplantation
Interleukin-17 (IL-17), a proinflammatory cytokine primarily produced by Th17 cells, plays a complex role in transplant immunology. Its involvement in graft-versus-host disease (GvHD) and immune regulation following hematopoietic cell transplantation (HCT) has garnered significant clinical interest, though findings remain inconsistent. This narrative review summarizes clinical studies in human HCT recipients investigating IL-17 cytokine levels, Th17 cell activity, and IL-17 gene polymorphisms associated with transplant outcomes. While several studies report associations between elevated IL-17 or Th17 levels and increased GvHD risk, results vary widely due to differences in study design, patient populations, and measurement methods. IL-17 is a promising, though context-dependent, biomarker and therapeutic target in HCT. Its dual roles in promoting inflammation and supporting antimicrobial defense complicate therapeutic modulation. Future studies should focus on standardized assays, multi-omics approaches, and longitudinal designs to clarify its clinical utility. Tailored strategies that modulate IL-17 without impairing immune reconstitution or graft-versus-leukemia effects are likely to guide future interventions.
- 16 October 2025
- Published by Taylor & Francis in Expert Review of Clinical Immunology
- Vol. 21 (11) , 1643-1655
Interleukin-17 and transplant immunology: clinical evidence from hematopoietic cell transplantation
Interleukin-17 (IL-17), a proinflammatory cytokine primarily produced by Th17 cells, plays a complex role in transplant immunology. Its involvement in graft-versus-host disease (GvHD) and immune regulation following hematopoietic cell transplantation (HCT) has garnered significant clinical interest, though findings remain inconsistent. This narrative review summarizes clinical studies in human HCT recipients investigating IL-17 cytokine levels, Th17 cell activity, and IL-17 gene polymorphisms associated with transplant outcomes. While several studies report associations between elevated IL-17 or Th17 levels and increased GvHD risk, results vary widely due to differences in study design, patient populations, and measurement methods. IL-17 is a promising, though context-dependent, biomarker and therapeutic target in HCT. Its dual roles in promoting inflammation and supporting antimicrobial defense complicate therapeutic modulation. Future studies should focus on standardized assays, multi-omics approaches, and longitudinal designs to clarify its clinical utility. Tailored strategies that modulate IL-17 without impairing immune reconstitution or graft-versus-leukemia effects are likely to guide future interventions.
- Open Access
- 28 September 2025
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 52 (9)
Maternal Plasma Levels of MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 as Predictive Biomarkers of Preeclampsia
Background: Preeclampsia (PE), a severe pregnancy complication, is a major contributor to maternal and perinatal morbidity and mortality worldwide. Matrix metalloproteinases (MMPs) and their tissue inhibitors of metalloproteinases (TIMPs) are implicated in the pathogenesis of PE. This study aimed to evaluate maternal plasma levels of MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 in normal and preeclamptic pregnancies across gestational trimesters to assess their predictive value. Methods: This case-control study included a total of 138 pregnant women: 72 with normal pregnant women (controls) and 66 women diagnosed with PE, recruited at Hanoi Obstetrics and Gynecology Hospital between July 2022 and June 2024. In the second trimester (14–28 weeks), the PE and control groups included 14 and 18 women, respectively. In the third trimester (29–41 weeks), the study included 52 women with PE and 54 controls. Plasma concentrations of MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 were measured using enzyme-linked immunosorbent assay (ELISA). Correlations between MMPs, TIMPs, MMP/TIMP ratios, and PE severity indices were analyzed using Spearman’s correlation. Receiver operating characteristic (ROC) analysis evaluated the diagnostic and predictive utility of these markers. Results: Maternal plasma levels of MMP-2 and TIMP-2 were significantly higher in the PE group compared to controls during both the second and third trimesters (p < 0.05). The MMP-2/TIMP-2 ratio was significantly lower in the PE group during the third trimester (p = 0.002). MMP-3 levels were markedly elevated in PE patients (p < 0.001) and were positively correlated with plasma creatinine and proteinuria. In contrast, MMP-9 levels were significantly reduced in the PE group across both trimesters (p < 0.05), whereas TIMP-1 levels showed no significant difference between groups. Notably, MMP-9 was strongly correlated with TIMP-1 in PE, and both markers correlated with systolic blood pressure (SBP). ROC curve analysis indicated the combination of MMP-2 and TIMP-2 as the best predictor of PE in the second trimester, while TIMP-2 was the most predictive marker in the third trimester. Conclusions: Elevated plasma MMP-2 and TIMP-2 levels, particularly in the second trimester, show potential as biomarkers for identifying patients at risk of PE. TIMP-2 appears promising for prediction in the third-trimester. These findings warrant further investigation for potential clinical application.
- 28 September 2025
- Published by IMR Press in Clinical and Experimental Obstetrics & Gynecology
- Vol. 52 (9)
Open AccessMaternal Plasma Levels of MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 as Predictive Biomarkers of Preeclampsia
Background: Preeclampsia (PE), a severe pregnancy complication, is a major contributor to maternal and perinatal morbidity and mortality worldwide. Matrix metalloproteinases (MMPs) and their tissue inhibitors of metalloproteinases (TIMPs) are implicated in the pathogenesis of PE. This study aimed to evaluate maternal plasma levels of MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 in normal and preeclamptic pregnancies across gestational trimesters to assess their predictive value. Methods: This case-control study included a total of 138 pregnant women: 72 with normal pregnant women (controls) and 66 women diagnosed with PE, recruited at Hanoi Obstetrics and Gynecology Hospital between July 2022 and June 2024. In the second trimester (14–28 weeks), the PE and control groups included 14 and 18 women, respectively. In the third trimester (29–41 weeks), the study included 52 women with PE and 54 controls. Plasma concentrations of MMP-2, MMP-3, MMP-9, TIMP-1, and TIMP-2 were measured using enzyme-linked immunosorbent assay (ELISA). Correlations between MMPs, TIMPs, MMP/TIMP ratios, and PE severity indices were analyzed using Spearman’s correlation. Receiver operating characteristic (ROC) analysis evaluated the diagnostic and predictive utility of these markers. Results: Maternal plasma levels of MMP-2 and TIMP-2 were significantly higher in the PE group compared to controls during both the second and third trimesters (p < 0.05). The MMP-2/TIMP-2 ratio was significantly lower in the PE group during the third trimester (p = 0.002). MMP-3 levels were markedly elevated in PE patients (p < 0.001) and were positively correlated with plasma creatinine and proteinuria. In contrast, MMP-9 levels were significantly reduced in the PE group across both trimesters (p < 0.05), whereas TIMP-1 levels showed no significant difference between groups. Notably, MMP-9 was strongly correlated with TIMP-1 in PE, and both markers correlated with systolic blood pressure (SBP). ROC curve analysis indicated the combination of MMP-2 and TIMP-2 as the best predictor of PE in the second trimester, while TIMP-2 was the most predictive marker in the third trimester. Conclusions: Elevated plasma MMP-2 and TIMP-2 levels, particularly in the second trimester, show potential as biomarkers for identifying patients at risk of PE. TIMP-2 appears promising for prediction in the third-trimester. These findings warrant further investigation for potential clinical application.